Fig. 3

H. pylori detection in DNA from biopsies of patients with gastric pathology and genotyping of vacA and status of cagA and babA2. a PCR amplification product of 16S rRNA gene in chronic gastritis patients. Lane 1 1 kb plus molecular weight marker; lane 2 positive control (DNA from H. pylori 26695 strain); lanes 3, 6, 7 negative samples; lanes 4, 5 positive samples; lane 8 negative control (without DNA). b PCR amplification product of 16S rRNA gene in gastric ulcer patients. Lane 1 1 kb plus molecular weight marker; lane 2 negative control (without DNA); lane 3 positive control (DNA from H. pylori 26695 strain); lanes 4, 8 positive samples; lanes 5–7 negative samples. c PCR amplification product of 16S rRNA gene in gastric cancer patients. Lane 1 1 kb plus molecular weight marker; lane 2 negative control (without DNA); lane 3 positive control (DNA from H. pylori 26695 strain); lanes 4, 5 negative samples; lanes 6–8 positive samples. d vacA genotypes. Lane 1 plus molecular weight marker 123 bp; lane 2 negative control (without DNA); lanes 3, 4 positive control (DNA from H. pylori ATCC 43504 strain vacA s1m1 genotype); lanes 5, 6 DNA from gastric biopsy with H. pylori vacA s1m1; lanes 7, 8 DNA from gastric biopsy with H. pylori vacA s2m2. e PCR amplification product of cagA gene. Lane 1 1 kb plus molecular weight marker; lane 2 negative control (without DNA); lane 3 positive control (DNA from H. pylori J99 strain cagA-positive); lanes 4, 5 clinical samples with H. pylori cagA-positive, lanes 6-8 clinical samples H. pylori cagA-negative. f PCR amplification product of babA2 gene. Lane 1 1 kb plus molecular weight marker; lane 2 negative control (without DNA), lane 3 positive control (DNA from H. pylori J99 strain babA2-positive); lanes 4, 5 clinical samples H. pylori babA2-positive; lanes 6–8 clinical samples H. pylori babA2-negative